Contrasting 60 Degrees Pharmaceuticals (NASDAQ:SXTP) and VBI Vaccines (NASDAQ:VBIV)

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Insider and Institutional Ownership

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are held by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of VBI Vaccines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for 60 Degrees Pharmaceuticals and VBI Vaccines, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	0	1	1	0	2.50
VBI Vaccines	0	0	0	0	N/A

60 Degrees Pharmaceuticals currently has a consensus target price of $2.40, indicating a potential upside of 42.86%. Given 60 Degrees Pharmaceuticals’ higher possible upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than VBI Vaccines.

Earnings and Valuation

This table compares 60 Degrees Pharmaceuticals and VBI Vaccines’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$250,000.00	11.89	-$3.77 million	($1.04)	-1.62
VBI Vaccines	$9.41 million	0.05	-$92.84 million	N/A	N/A

60 Degrees Pharmaceuticals has higher earnings, but lower revenue than VBI Vaccines.

Profitability

This table compares 60 Degrees Pharmaceuticals and VBI Vaccines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	N/A	N/A	-98.31%
VBI Vaccines	-881.79%	-525.42%	-45.87%

Summary

60 Degrees Pharmaceuticals beats VBI Vaccines on 6 of the 10 factors compared between the two stocks.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

About VBI Vaccines

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.